Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of LY2963016 U-200 vs U-100 in Healthy Subjects
NCT02955953Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin glargine in diabetes mellitus (DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration at 48 hours and Area Under the Concentration Versus Time Curve at 48 hours. Started Nov 2016; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT02955953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955953.